Evaluating the Role of Immune Responses in the Emergence of Protease Inhibitor Mutations

Completed

Conditions studied: Hepatitis C

In brief

The major goal of this project is to identify the role of the immune responses in the emergence of protease inhibitor mutants during therapy.

Key facts

Study ID

NCT01517529

Run by

University of Cincinnati

People needed

10

Starts

2012-01-01

Expected to finish

2014-12-01

Last updated by the study team

2015-11-20

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

• Treatment naïve chronically HCV-infected patients.
• Patients with a history of inflammatory bowel diseases (IBD) or suspected IBD, autoimmune diseases, including rheumatoid arthritis, and any patients on systemic immunomodulators.
• Pregnancy
• HIV

Where it is running

• University of Cincinnati — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.